Q&A With Dr. Kyle Flanigan, Ph.D., Co-Founder And CEO Of USSF

August 3, 2022
USSF co-founders Dr. Kyle Flanigan, Ph.D. (on right) and Dr. Garry Morefield, Ph.D. (on the left)
Dr. Kyle Flanigan, Ph.D., discusses the benefits of an oral COVID-19 vaccine.

Doctors are still trying to perfect the COVID-19 vaccines. Dr. Kyle Flanigan, Ph.D., co-founder and CEO of USSF, discussed his work with Dr. Garry Morefield, Ph.D., on an oral vaccine against the virus.

(Pharm Exec): What are the benefits to an oral vaccine compared to an injection?

Flanigan: We believe our oral platform is the future of vaccines. It is evident that an oral vaccine does not require needles, thus the additional benefits include ease of use, non-invasive delivery method, and the manufacturing is significantly less risky. The US Specialty Formulations LLC (USSF) COV2-OGEN1 oral vaccine is stable to very high temperatures and does not need the same cold-chain logistics and storage requirements as other vaccines that are currently on the market.

A significant feature is that it is stable up to 140° Fahrenheit for more than three months. Further, an oral vaccine does not require a health care practitioner to administer. For a country looking to vaccinate its population, it is an ideal option as more people are likely to take it.

Our vaccine shows a significant IgA response in both serum and mucosal systems which is considered key for preventing respiratory infection. It is an oral vaccine that meets people’s lifestyles.

Read More

Comments are closed.